Advertisement

Cardiovascular Drugs and Therapy

, Volume 12, Issue 2, pp 197–210 | Cite as

Selection of Drug Therapy in Stable Angina Pectoris

  • Stefano Savonitto
  • Diego Ardissino
Article

Abstract

Drug therapy in stable angina has two aims: the prevention of major cardiac events (such as unstable angina, myocardial infarction, or death) and the control of chest pain and transient myocardial ischemia. Given the low incidence of major cardiac events in patients with stable angina, primary preventive studies are scarce because they require a large sample size and long-term follow-up. Thus far, only aspirin and some lipid-lowering agents have been shown to be effective for this purpose. Antiischemic drugs reduce the imbalance between myocardial oxygen demand and supply, either by reducing oxygen consumption or by increasing coronary blood flow. The ideal approach would be to target drug therapy against the ischemia-inducing factor in each patient. The characteristics of anginal symptoms do not seem to help in selecting medical therapy, whereas a standard exercise test and a provocative test of coronary vasoconstriction may provide useful information in order to select patients who will preferentially respond to either a beta-blocker or a calcium antagonist. The combination of two or more anti-ischemic drugs does not seem to be any more effective than an adequately titrated monotherapy in reducing the occurrence of myocardial ischemia in individual patients. Combination therapy in stable coronary artery disease should include an individually selected and optimally titrated anti-ischemic agent and aspirin, with the addition of a lipid-lowering agent in patients with even mild hypercholesterolemia.

ngina pectoris drug therapy beta-adrenergic blockers calcium channel blockers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Specchia G, Ghio S. Pathophysiology, clinical presentation, and prognosis of angina pectoris. In: Ardissino D, Opie LH, Savonitto S, eds. Drug Evaluation in Angina Pectoris. Boston: Kluwer Academic, 1994:3-11.Google Scholar
  2. 2.
    Epstein SE, Talbot TL. Dynamic coronary tone in the precipitation, exacerbation and relief of angina pectoris. Am J Cardiol 1981;48:797-803.Google Scholar
  3. 3.
    Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilatation in ischemic manifestations of coronary artery disease. Circulation 1993;87(Suppl. V):V56-V66.Google Scholar
  4. 4.
    Feigl EO. The paradox of adrenergic coronary vasoconstriction. Circulation 1987;76:737-745.Google Scholar
  5. 5.
    Vita JA, Treasure CB, Nabel EG, et al. The coronary vasomotor response to acetylcholine relates to risk factors for coronary disease. Circulation 1990;81:491-497.Google Scholar
  6. 6.
    Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990;81:850-859.Google Scholar
  7. 7.
    Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79:287-291.Google Scholar
  8. 8.
    Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87(Suppl. V):V51-V55.Google Scholar
  9. 9.
    Yeung AC, Raby KE, Ganz P, Selwyn P. New insights into the management of myocardial ischemia. Am J Cardiol 1992;70:8G–13G.Google Scholar
  10. 10.
    Harrison DJ, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80: 1808-1811.Google Scholar
  11. 11.
    Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.Google Scholar
  12. 12.
    Brown BG, Bolsen E, Peterson RB, Pierce CD, Dodge HT. The mechanism of nitroglycerin actions: Stenosis vasodilatation as a major component of the drug response. Circulation 1981;64:1089-1097.Google Scholar
  13. 13.
    Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;5:865-876.Google Scholar
  14. 14.
    Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996;93:1380-1387.Google Scholar
  15. 15.
    Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol 1997;79:24-28.Google Scholar
  16. 16.
    Task Force on the Management of Stable Angina Pectoris. Guidelines. Management of stable angina pectoris. Eur Heart J 1997;18:394-413.Google Scholar
  17. 17.
    Hochrein J, Mark DB. CABG, PTCA or medical treatment for coronary artery disease. Prim Cardiol 1995;21:21-26.Google Scholar
  18. 18.
    Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the coronary artery bypass graft surgey trialists collaboration. Lancet 1994;344: 563-570.Google Scholar
  19. 19.
    Chen L. Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and cardiac events in patients with “stabilized” unstable angina pectoris. Circulation 1995;91:2319-2324.Google Scholar
  20. 20.
    Juul-Moeller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.Google Scholar
  21. 21.
    Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the asymptomatic cardiac ischemia pilot study. J AmCol Cardiol 1997; 29:1483-1489.Google Scholar
  22. 22.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 349-360.Google Scholar
  23. 23.
    TheRISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.Google Scholar
  24. 24.
    Nyman I, Larsson H, Wallentin L, and the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia. Lancet 1992;340:497-501.Google Scholar
  25. 25.
    Harpaz D, Benderly M, Kishon Y, Goldbourt U, Behar S, and the Israeli BIP Investigators. Reduced mortality among women with chronic coronary artery disease taking aspirin. Circulation 1995;92(Suppl. I):I197.Google Scholar
  26. 26.
    Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.Google Scholar
  27. 27.
    Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-527.Google Scholar
  28. 28.
    MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.Google Scholar
  29. 29.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.Google Scholar
  30. 30.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.Google Scholar
  31. 31.
    Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.Google Scholar
  32. 32.
    Pepine CJ, Cohn PF, Deedwania PC, et al. for the ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. Circulation 1994;90:762-768.Google Scholar
  33. 33.
    Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm. Eur Heart J 1996;17:76-81.Google Scholar
  34. 34.
    Dargie HJ, Ford I, Fox KM on befalf of the TIBET study group. Total Ischemic Burden European Trial (TIBET). Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104-112.Google Scholar
  35. 35.
    Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259:1976-1982.Google Scholar
  36. 36.
    Borhani MO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276:785-91.Google Scholar
  37. 37.
    Agabiti Rosei E, Dal Palu' C, Leonetti G, Magnani B, Pessina A, Zanchetti A, on behalf of the VHAS investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study: J Hypertens 1997;15:1337-1344.Google Scholar
  38. 38.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.Google Scholar
  39. 39.
    DAVIT II Trial. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial-DAVIT II). Am J Cardiol 1990; 66:779-785.Google Scholar
  40. 40.
    Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non Q-wave myocardial infarction: Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-429.Google Scholar
  41. 41.
    Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA 1988;260:2088-2093.Google Scholar
  42. 42.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.Google Scholar
  43. 43.
    CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.Google Scholar
  44. 44.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.Google Scholar
  45. 45.
    Quyyumi AA, Wright C, Mockus LJ, Fox KM. Mechanisms of nocturnal angina pectoris: Importance of increased myocardial oxygen demand in patients with severe coronary artery disease. Lancet 1984;2:1207-1209.Google Scholar
  46. 46.
    Ardissino D, Savonitto S, Egstrup K, et al. Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. Am J Cardiol 1991;67:946-952.Google Scholar
  47. 47.
    Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. Am J Cardiol 1985;56:30E-33E.Google Scholar
  48. 48.
    Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment for stable angina pectoris. Results of the International Multicenter Angina Exercise study (IMAGE). J Am Coll Cardiol 1995;25:1516-1521.Google Scholar
  49. 49.
    Nesto RW, Zarich SW, Kowalchuck GJ, Kenigsberg AE, Shurmur SW, McAuliffe LS. Frequency of symptoms suggestive of dynamic coronary disease in patients referred for coronary angiography. Am J Cardiol 1989;64:1374-1376.Google Scholar
  50. 50.
    Levantesi D, Marraccini P, Michelassi C, DalleVacche M, L' Abbate A. Elective response to propranolol or verapamil in ischemia on effort. Can J Cardiol 1989;5:299-304.Google Scholar
  51. 51.
    Yasue H, Nagao M, Omote S, Takizawa A, Miwa K, Tanaka S. Coronary arterial spasm and Prinzmetal's variant angina induced by hyperventilation and Tris buffer infusion. Circulation 1978;58:56-62.Google Scholar
  52. 52.
    Ardissino D, DeServi S, Barberis P, et al. Significance of hyperventilation-induced ST-segment depression in patients with coronary artery disease. J AmColl Cardiol 1989; 13:804-809.Google Scholar
  53. 53.
    Ardissino D, Savonitto S, Zanini P, et al. Ability of calcium-entry blockade by felodipine to disclose different pathogenetic mechanisms behind hyperventilation-induced myocardial ischemia in men. Am J Cardiol 1990;66:1304-1308.Google Scholar
  54. 54.
    Previtali M, Barberis P, Ardissino D. Provocative testing of coronary vasocostriction. In: Ardissino D, Opie LH, Savonitto S, eds. Drug Evaluation in Angina Pectoris. Boston: Kluwer Academic, 1994:85-101.Google Scholar
  55. 55.
    Ardissino D, Barberis P, DeServi S, et al. Usefulness of the hyperventilation test in stable exertional angina pectoris in selecting medical therapy. Am J Cardiol 1990;65:417-421.Google Scholar
  56. 56.
    Krikler DM, Harris MB, Rowland E. Calcium-channel blockers and beta blockers: Advantages and disadvantages of combination therapy in chronic stable angina pectoris. Am Heart J 1982;104:702-708.Google Scholar
  57. 57.
    Kostuk WJ, Pflugfelder P. Comparative effects of calcium entry-blocking drugs, β-blocking drugs, and their combination in patients with chronic stable angina. Circulation 1987;75(Suppl V): V114-V121.Google Scholar
  58. 58.
    Broustet JP, Mora B, Douard H. Mono-or combination therapy for stable angina pectoris. J Cardiovasc Pharmacol 1987;10(Suppl. 2):S38-S47.Google Scholar
  59. 59.
    Strauss WE, Parisi AF. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Ann Intern Med 1988;109:570-581.Google Scholar
  60. 60.
    Chan P, Heo J, Garibian G, Askenase A, Segal BL, Iskandrian AS. The role of nitrates, beta blockers, and calcium antagonists in stable angina pectoris. Am Heart J 1988;116: 838-848.Google Scholar
  61. 61.
    Packer M. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989;320:709-718.Google Scholar
  62. 62.
    Thadani U. Combination therapy for the angina patient. J Am Coll Cardiol 1989;5:15-19Google Scholar
  63. 63.
    Crawford MH. The role of triple therapy in patients with chronic stable angina pectoris. Circulation 1987;75(Suppl. V):V122-V127.Google Scholar
  64. 64.
    Thadani U, Chohan A. Chronic stable angina pectoris. Strategies for effective drug therapy. Postgrad Med 1995;98: 178-188.Google Scholar
  65. 65.
    Opie LH. Pharmacologic options for the treatment of ischemic disease. In: Smith TW, ed. Cardiovascular Therapeutics. Philadelphia: WB Saunders, 1996:22-57Google Scholar
  66. 66.
    Thadani U. Dose-response relationships and combination studies with antianginal agents. In: Ardissino S, Opie LH, Savonitto S, eds. Drug Evaluation in Angina Pectoris. Boston: Kluwer Academic, 1994:151-156.Google Scholar
  67. 67.
    Parker JO. Nitrate therapy in stable angina pectoris. N Engl J Med 1987;316:1635-1642.Google Scholar
  68. 68.
    Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994;8:625-633.Google Scholar
  69. 69.
    Thadani U, Lipicky R. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994;8: 611-623.Google Scholar
  70. 70.
    Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: Results of the second Transdermal Intermittent Dosing Evaluation Study. J Am Coll Cardio 1997; 30:955-961.Google Scholar
  71. 71.
    Ekelund LG, Oro L. Antianginal efficacy of nifedipine with and without a beta-blocker; studies with exercise test: A double-blind, randomized subacute study. Clin Cardiol 1979;2:203-211.Google Scholar
  72. 72.
    Lynch P, Dargie H, Krikler S, Krikler D. Objective assessment of antianginal treatment: A double-blind comparison of propranolol, nifedipine, and their combination. Br Med J 1980;281:184-187.Google Scholar
  73. 73.
    Tweddel AC, Beattie JM, Murray RG, Hutton I. The combination of nifedipine and propranolol in the management of patients with angina pectoris. Br J Clin Pharmacol 1981;12: 229-233.Google Scholar
  74. 74.
    Dargie HJ, Lynch PG, Krikler DM, Harris L, Krikler S. Nifedipine and propanolol: A beneficial drug interaction. Am J Med 1981;71:676-682.Google Scholar
  75. 75.
    Jenkins RM, Nagle RE. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad Med J 1982;58:697-700.Google Scholar
  76. 76.
    Braun S, Terdiman R, Berenfeld D, Laniado S. Clinical and hemodynamic effects of combined propranolol and nifedipine therapy versus propranolol alone in patients with angina pectoris, Am Heart J 1985;109:478-485.Google Scholar
  77. 77.
    Johnston DL, Losoway R, Humen DP, Kostuk WJ, Mickle P. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol 1985;55:680-687.Google Scholar
  78. 78.
    Uusitalo A, Arstila M, Bae EA, et al. Metoprolol, nifedipine and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733-737.Google Scholar
  79. 79.
    Findlay IN, MacLeod K, Ford M Gillen G, Elliott AT, Dargie HJ. Treatment of angina pectoris with nifedipine and atenolol: Efficacy and effect on cardiac function. Br Heart J 1986;55:240-245.Google Scholar
  80. 80.
    Stone PH, Ware JH, DeWood MA, et al. The efficacy of the addition of nifedipine in patients with mixed angina compared to patients with classic exertional angina: A multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J 1988;116:961-971.Google Scholar
  81. 81.
    Egstrup K. Randomized double-blind comparison of metoprolol, nifedipine, and their combination in chronic stable angina: Effects on total ischemic activity and heart rate at onset of ischemia. Am Heart J 1988;116:971-978.Google Scholar
  82. 82.
    Hill JA, Gonzalez JI, Kolb R, Pepine CJ. Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia. Am J Cardiol 1991;67:671-675.Google Scholar
  83. 83.
    Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338:1036-1039.Google Scholar
  84. 84.
    Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: A double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409-17.Google Scholar
  85. 85.
    Siu SC, Jacoby RM, Phillips RT, Nesto RW. Comparative efficacy of nifedipine gastrointestinal therapeutic system when added to beta blockers in stable angina pectoris. Am J Cardiol 1993;71:887-892.Google Scholar
  86. 86.
    Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine in comparison with monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise Study (IMAGE). J Am Coll Cardiol 1996;27:311-316.Google Scholar
  87. 87.
    DiBianco R, Schoomaker FW, Sing JB, et al. Amlodipine combined with beta blockade for chronic angina: Results of a multicenter, placebo-controlled, randomized double-blind study. Clin Cardiol 1992;15:519-524.Google Scholar
  88. 88.
    Davies RF, Habibi H, Klinke WP, et al. for the Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatori monitoring. J Am Coll Cardiol 1995;25:619-625.Google Scholar
  89. 89.
    Sangiorgio P, Di Pasquale G, Savonitto S, et al. Felodipine in chronic stable angina: A randomized, double-blind, placebo-controlled, crossover study. Eur Heart J 1990;11:1011-1017.Google Scholar
  90. 90.
    Morse JR. Comparison of combination nifedipine-propranolol and diltiazem propranolol with high dose diltiazem monotherapy for stable angina pectoris. Am J Cardiol 1988; 62:1029-1032.Google Scholar
  91. 91.
    Hung J, Lamb IH, Connolly SJ, Jutzy RR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: A double-blind, randomized, and placebo-controlled study. Circulation 1983;68:560-567.Google Scholar
  92. 92.
    Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985;71:951-957.Google Scholar
  93. 93.
    Winniford MD, Fulton KL, Corbett JR, Croft CH, Hillis LD. Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: A randomized, double-blind, crossover study. Am J Cardiol 1985;55:281-285.Google Scholar
  94. 94.
    Findlay IN, MacLeod K, Gillen G, Elliott AT, Aitchison T, Dargie HJ. A double blind placebo controlled comparison of verapamil, atenolol, and their combination. Br Heart J 1987; 57:336-343.Google Scholar
  95. 95.
    Pepine CJ. Is silent ischemia a treatable risk factor in patients with angina pectoris? Circulation 1990;82(Suppl. II):II135-II142.Google Scholar
  96. 96.
    Quyyumi AA. Evaluation of transient myocardial ischemia by Holter monitoring. In: Ardissino S, Opie LH, Savonitto S, eds Drug Evaluation in Angina Pectoris. Boston: Kluwer Academic, 1994:53-72.Google Scholar
  97. 97.
    Stone PH, Chaitman BR, McMahon RP, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease. Circulation 1996;94:1537-1544.Google Scholar
  98. 98.
    Cecchi AC, Dovellini EV, Marchi F, et al. Silent myocardial ischemia during ambulatory electrocardiographic monitoring in patients with effort angina. J Am Coll Cardiol 1983; 1:934-939.Google Scholar
  99. 99.
    Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot Study. J Am Coll Cardiol 1997;29:1483-1489.Google Scholar
  100. 100.
    Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990;81:748-756.Google Scholar
  101. 101.
    McLenachan JM, Weidinger FS, Barry J, et al. Relations between heart rate, ischemia, and drug therapy during daily life in patients with coronary artery disease. Circulation 1991;83:1263-1270.Google Scholar
  102. 102.
    Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 1992;20:1092-1098.Google Scholar
  103. 103.
    Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 1990;82:1962-1972.Google Scholar
  104. 104.
    Theroux P, Baird M, Juneau, et al. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and durng exercise. Circulation 1991;84:15-22.Google Scholar
  105. 105.
    van Boven AdJ, Jukema W, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG on behalf of the REGRESS Study Group. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503-1505.Google Scholar
  106. 106.
    Gandhi MH, Wood DA, Lampe FC. Characteristics and clinical significance of ambulatory ischemia in men and women in the general population presenting with angina pectoris. J Am Coll Cardiol 1994;23:74-81.Google Scholar
  107. 107.
    Savonitto S, Merlini PA. Clinical value of anginal symptoms and their assessment in drug trials. In: Ardissino S, Opie LH, Savonitto S, eds. Drug Evaluation in Angina Pectoris. Boston: Kluwer Academic, 1994:15-30.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Stefano Savonitto
    • 1
  • Diego Ardissino
    • 2
  1. 1.Second Division of CardiologyOspedale Niguarda Ca’ GrandaMilan
  2. 2.Division of Cardiology, IRCCS Policlinico San MatteoUniversity of PaviaPaviaItaly

Personalised recommendations